Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane

Metastatic Breast ◽

Phase Iii ◽

Eribulin Mesylate ◽

Phase Iii Study ◽

Previously Treated ◽

Locally Recurrent ◽

Versus Treatment

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

European Journal of Cancer ◽

10.1016/j.ejca.2012.04.022 ◽

2012 ◽

Vol 48 (17) ◽

pp. 3140-3149 ◽

Cited By ~ 11

Author(s):

I. Lang ◽

M.J. Inbar ◽

Z. Kahán ◽

R. Greil ◽

S. Beslija ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Study ◽

Her 2 ◽

Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study.

10.1158/0008-5472.sabcs-4116 ◽

2009 ◽

Cited By ~ 30

Author(s):

LY Dirix ◽

G Romieu ◽

L Provencher ◽

D Grimes ◽

L de Souza Viana ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Abstract P6-13-02: Survival Outcomes with Eribulin Mesylate vs. Treatment of the Physician's Choice (TPC) in Heavily Pretreated Subjects with Locally Recurrent or Metastatic Breast Cancer in North America, Western Europe, and Australia: Results of the Phase III EMBRACE Study

10.1158/0008-5472.sabcs10-p6-13-02 ◽

2010 ◽

Author(s):

LT Vahdat ◽

CJ Twelves ◽

S Seegobin ◽

C Akerele ◽

J Wanders ◽

...

Keyword(s):

Breast Cancer ◽

North America ◽

Western Europe ◽

Metastatic Breast ◽

Phase Iii ◽

Survival Outcomes ◽

Eribulin Mesylate ◽

Heavily Pretreated ◽

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

10.1158/0008-5472.sabcs12-s6-6 ◽

2012 ◽

Cited By ~ 24

Author(s):

PA Kaufman ◽

A Awada ◽

C Twelves ◽

L Yelle ◽

EA Perez ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Eribulin Mesylate ◽

Previously Treated

A randomized phase III study of vinflunine versus an alkylating agent of physician’s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.1031 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 1031-1031 ◽

Cited By ~ 6

Author(s):

Javier Cortes ◽

Christelle Levy ◽

Yuri Demidchik ◽

Laslo Roman ◽

Hugues Pierre Bourgeois ◽

...

Keyword(s):

Breast Cancer ◽

Alkylating Agent ◽

Vinca Alkaloid ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Previously Treated

Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC).

10.1158/0008-5472.sabcs-1035 ◽

2009 ◽

Cited By ~ 2

Author(s):

A Wardley ◽

C Lohrisch ◽

A Joy ◽

S Young ◽

F Yi ◽

...

Keyword(s):

Breast Cancer ◽

Anticoagulation Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Thromboembolic Events ◽

Phase Iii Study ◽

Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study.

10.1158/0008-5472.sabcs-1027 ◽

2009 ◽

Cited By ~ 4

Author(s):

A Chan ◽

L Vanlemmens ◽

PF Conte ◽

J Beith ◽

H Samonigg ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Study ◽

Abstract P6-14-05: Final Overall Survival Analysis of the TBP Phase III Study (GBG 26/BIG 3-05): Capecitabine vs. Capecitabine + Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing during Trastuzumab Treatment

10.1158/0008-5472.sabcs10-p6-14-05 ◽

2010 ◽

Author(s):

G von Minckwitz ◽

K Schwedler ◽

M Schmidt ◽

J Barinoff ◽

C Mundhenke ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Metastatic Breast ◽

Phase Iii ◽

Her2 Positive ◽

Trastuzumab Treatment ◽

Phase Iii Study ◽

Overall Survival Analysis

Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2010.n.023 ◽

2010 ◽

Vol 10 (2) ◽

pp. 160-163 ◽

Cited By ~ 76

Author(s):

Chris Twelves ◽

Javier Cortes ◽

Linda T. Vahdat ◽

Jantien Wanders ◽

Corina Akerele ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Eribulin Mesylate ◽

Phase Iii Trials ◽

Pretreated Patients ◽

Incidence of peripheral neuropathy associated with eribulin mesylate versus vinorelbine in patients with metastatic breast cancer: sub-group analysis of a randomized phase III study

Supportive Care in Cancer ◽

10.1007/s00520-019-05112-5 ◽

2019 ◽

Vol 28 (8) ◽

pp. 3819-3829

Author(s):

Ying Wu ◽

Qin Wang ◽

Jian Zhang ◽

Jun Cao ◽

Biyun Wang ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Group Analysis ◽

Metastatic Breast ◽

Phase Iii ◽

Eribulin Mesylate ◽

Phase Iii Study